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Mitogen-activated protein kinases (MAPK) promote MAPK-
activated protein kinase activation. In the MAPK pathway
responsible for cell growth, ERK2 initiates the first phosphory-
lation event on RSK1, which is inhibited by Ca2-binding S100
proteins inmalignantmelanomas.Here,wepresent a detailed in
vitro biochemical and structural characterization of the
S100B-RSK1 interaction. The Ca2-dependent binding of
S100B to the calcium/calmodulin-dependent protein kinase
(CaMK)-type domain of RSK1 is reminiscent of the better
known binding of calmodulin to CaMKII. Although S100B-
RSK1 and the calmodulin-CAMKII system are clearly distinct
functionally, they demonstrate how unrelated intracellular
Ca2-binding proteins could influence the activity of the
CaMK domain-containing protein kinases. Our crystallo-
graphic, small angle x-ray scattering, and NMR analysis
revealed that S100B forms a “fuzzy” complex with RSK1 pep-
tide ligands. Based on fast-kinetics experiments, we conclude
that the binding involves both conformation selection and
induced fit steps. Knowledge of the structural basis of
this interaction could facilitate therapeutic targeting of
melanomas.
The vertebrate-specific S100 proteins belong to the EF-
hand-containing, Ca2-binding superfamily of proteins with
more than 20 paralogs in the human proteome (1, 2). They are
small (100 amino acids) and mostly homodimeric proteins
where eachmonomer can bind two calcium ions. In their Ca2-
bound form, eachmonomer exposes a hydrophobic surface and
becomes capable of binding to target proteins. In most cases,
two partner proteins bind to one S100 dimer symmetrically;
however, there are a few examples where an elongated motif
interacts with the two identical hydrophobic grooves simulta-
neously and asymmetrically (3, 4). S100 proteins can be found
both intra- and extracellularly. On the cell surface, they can
bind to receptors (such as receptor for advanced glycosylation
end product) and activate ERK/p38 mitogen-activated protein
kinase (MAPK) pathways indirectly (5, 6). Despite the fact that
these small proteins have been extensively studied for decades,
the precise and specific intracellular role of most S100 proteins
still remains to be determined.
It has recently been shown that S100B can form a complex
with ribosomal S6 kinase 1 (RSK1) in malignant melanoma cell
lines, and this interaction negatively affects phosphorylation of
the C-terminal Ca2/calmodulin-dependent kinase (CaMK)3-
type domain of RSK1 by ERK1/2 (7). In malignant melanomas,
S100B expression is highly elevated, which can be used as a
prognosticmarker for the disease (8).Moreover, S100B is being
explored as a therapeutic target for treating melanomas by
inhibiting its protein-protein interactions (9).
RSK1 belongs to the group of MAPK-activated protein
kinases (MAPKAPK) (10). MAPKAPKs are downstream cyto-
plasmic targets of ERK and/or p38 MAPKs and belong to the
CaMK-type protein kinase superfamily (11). Inactive MAP-
KAPKs are in an autoinhibited form where the C-terminal
inhibitory helix (L) blocks substrate as well as ATP binding.
This inhibitory helix is followed by a short linker and an MAPK-
binding linear motif, where the latter determines MAPK binding
specificity (12, 13). The first step of MAPKAPK activation is acti-
vation loop (AL) phosphorylation by its cognateMAPK.Next, the
autoinhibitory helix is extruded by the phosphorylated AL via an
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unknown mechanism (14). Although most MAPKAPK proteins
contain a single catalytic domain, the RSK subfamilies are tandem
kinases; in addition to their C-terminal CaMK-type domain
(CTKD), they have an N-terminal AGC-type kinase domain
(NTKD).
The regulatory mechanism of CaMK-type kinases usually
involves intracellular Ca2 signals. These kinases have a regu-
latory C-terminal extension, and in the inactive form the first
segment of this tail forms a helical inhibitory helix that blocks
substrate or cofactor binding, whereas the second segment is
disordered. Upon Ca2 binding, calmodulin (CaM) opens up
andbinds to the unstructured tail and to the terminal part of the
inhibitory helix (15). This interaction remodels the inhibitory
segment and brings about an active kinase state (Fig. 1A). In
contrast, AGC-type kinases have a more complicated regula-
tion mechanism that includes multiple phosphorylation steps.
They also have a C-terminal regulatory element that includes
two short sequence motifs as follows: the turn motif and the
hydrophobic motif (HM). Upstream kinases phosphorylate the
HM and turn motif, which will bind to the N-lobe of the kinase
domain. Phospho-HMbinding remodels the allostericChelix
of the kinase domain, which in turn activates the kinase,
although phospho-turn motif will increase HM binding (16).
Fully active kinase requires another phosphorylation on its
AL. In some cases phospho-HM also has a binding partner in
trans; it can bind to an AGC master kinase, for example
phosphoinositide-dependent kinase 1 (PDK1), which will then
phosphorylate the AL (17).
Phosphorylation on the CaMK-type domain of RSK1 by acti-
vated ERK2 sets off the full multistep activation of RSK1 (Fig.
1B). In RSK1, the only known role of the C-terminal CaMK-
type kinase domain (CTKD) is the phosphorylation of the reg-
ulatory hydrophobic motif of the NTKD (18). The phos-
pho-HM of NTKD serves as an anchor motif for PDK1, which
will eventually phosphorylate the activation loop of NTKD,
resulting in an active kinase that can now phosphorylate a
diverse set of substrates downstream of RSK1 (17).
S100B binding to the CTKD of RSK1 may be intuitively sim-
ilar to typical CaMK activation. Inactive CaMKII has a very
similar structure to RSK1; moreover, both the structure and
function of S100B are analogous to that of calmodulin. In this
study, we have performed biochemical and structural charac-
terization of S100Bbinding toRSK1.We show that S100Bbinds
to a C-terminal RSK1 segment that is required not only for
ERK2 recruitment but also for the autoinhibition of the RSK1
CaMK-type domain. Interestingly, S100B not only directly
interferes with the assembly of the ERK2-RSK1 heterodimeric
complex, it also negatively affects the activity of theCaMK-type
domain of RSK1. The structural basis for this unusual dual-
inhibitory mechanism was revealed by combining high resolu-
tion x-ray crystallographic analysis with lower resolution solu-
tion small angle x-ray scattering andNMRspectroscopy studies
on a minimal S100B-RSK1 complex. This analysis revealed a
highly dynamic, fuzzy complex (19).We also found that a single
RSK1 fragment binds to an S100B dimer, which is rather
unusual in the symmetric homodimer-forming S100 protein
family (3). Kinetic studies indicated that S100B binding to the
CaMK-type domain involves both a conformational selection
and an induced fit step. Based on the results of our structural
analysis, it was possible to assign a structural state to all
observed kinetic steps. Overall, our study gives a detailed bio-
chemical insight into the S100B-RSK1 interaction and could
facilitate future drug design studies to treat malignant
melanomas.
Experimental Procedures
Protein/Peptide Expression and Purification—The cDNA of
S100 proteins, the RSK1CTKD construct containing the C-ter-
minal RSK1 region between residues 411 and 735, as well as
different peptides from RSK1 were cloned into modified pET
expression vectors. All protein constructs were expressed in
Escherichia coli Rosetta (DE3) pLysS (Novagen) cells with stan-
dard techniques. RSK1CTKD was expressed as N-terminal GST
fusion protein with a C-terminal non-cleavable hexahistidine
tag. S100B/A4/A2/P/A10 was cloned with an N-terminal TEV-
cleavable hexahistidine tag. All peptides were cloned with an
N-terminal GST fusion tag. For labeling, the peptide 689–735
contained an N-terminal Cys residue. The shorter reporter
peptide (residues 712–735)was chemically synthesized andwas
N-terminally labeled with carboxyfluorescein. The RSK1 HM
construct (AGAHQLFRGFSFVATG) was expressed as an
N-terminal GST fusion protein with a C-terminal non-cleav-
able hexahistidine tag. S100B/A4/A2/P was purified with a
nickel-affinity column and cleaved by TEV protease. After
complete cleavage, S100B/A4/A2/P was supplemented with
Ca2/Zn2 and injected into a phenyl-Sepharose column.
Elution was done with 5 mM EDTA, and the eluted fractions
were dialyzed against a Ca2/Zn2-containing buffer. After
cleavage, S100A10 was further purified by cation exchange
chromatography. For biochemicalmeasurements, double affin-
ity-purified RSK1 was used. For SAXS measurement, this dou-
ble-purified RSK1 was cleaved by the TEV protease, and the
sample was further purified on a HiTrap Blue-Sepharose col-
umn (GE Healthcare), and then it was complexed with S100B.
Peptides were captured by GST affinity purification. After TEV
cleavage, GST and TEV were precipitated by boiling the sam-
ple. The protein precipitation was spun down, and the super-
natant was further purified by reverse-phase HPLC on a Jupiter
300 C5 column (Phenomenex). After lyophilization, the pep-
FIGURE1.RegulationofCaMKdomain containingproteinkinaseactivity.
A, inactive CaMKII has an autoinhibitory C-terminal fragment (blue) that is
released by calmodulin binding (15). Many CaMK-type kinases share an anal-
ogous activation mechanism. B, RSK1 consists of two kinase domains (green)
and a flexible C-terminal tail (red) (13, 40). ERK2 (orange) binds directly to the
C-terminal linearmotif andphosphorylates the activation loopof theCTKDof
RSK1 (which is a CaMK-type kinase domain). Then the CTKD phosphorylates
the HM of the NTKD. The phosphorylated HM can anchor the AGC master
kinase PDK1, which will, in turn, activate the NTKD.
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tides were dissolved in water. For NMR experiments, the 15N-
labeled peptide was produced similarly, but before induction,
cells were transferred to a 15NH4Cl-containing minimal
medium. Labeling of cysteine-containing peptides was carried
out using 5-(iodoacetamido)fluorescein (Sigma), and the reac-
tion mixture was also purified by HPLC. HM peptide was pre-
pared by double affinity purification.
Crystallization, Data Collection, and Structural Deter-
mination—Crystallization samples contained 1mMS100Bmono-
mer and 2-fold excess (1 mM) of RSK1 peptide in each case.
Crystallization was done in a standard sitting drop vapor-diffu-
sion setup at 23 °C. The crystallization solution consisted of 0.1
M HEPES, pH 7, 150 mM NaCl, 20% PEG6000 in all four cases.
Crystals were supplemented with 10% glycerol before flash-
cooling in liquid nitrogen. Data were collected on the PXIII
beamline of the Swiss Light Source (Villigen) and on the ID23
and ID30 beamlines of ESRF (Grenoble, France) at 100K (Table
1). Data were processed with XDS.Matthews probability calcu-
lations indicate the highest probability of an asymmetric com-
plex forming between a single dimer of S100B and a single RSK1
peptide in all crystal forms (20). This was later confirmed after
the phase problem was solved by molecular replacement in
PHASER with a high resolution structure of S100B as a search-
ing model (21–23). The molecular replacement search identi-
fied a single S100B dimer in the asymmetric unit in all cases.
Structure refinementwas carried out in PHENIX, and structure
remodeling/buildingwas done inCoot (24, 25). The finalmodel
was refined to 2.4 Å resolution for crystal structure A (with
peptide 683–735), to 2.13 Å resolution for crystal structure A
(with peptide 689–735), to 2.7 Å resolution for the crystal
structure B (with peptide 696–735), and to 2.95 Å resolution
for the crystal structure C (with peptide 683–720) (Table 1).
Kinase Assays—Activated MAPKs were produced by co-ex-
pressing them with constitutively active forms of GST-tagged
MAPK kinases in E. coli with bicistronic modified pET vectors
as described before (13). MAPKs were purified by affinity puri-
fication using a HiTrap nickel column (GE Healthcare) fol-
lowed by ion exchange chromatography on a 1-ml Mono Q
column (GEHealthcare). 20 nM activatedMAPKwas incubated
with 1 M GST-eluted MAPKAPK substrates at room temper-
ature with increasing amounts of S100B. Kinase reactions were
carried out in 50 mM HEPES, pH 7.5, 100 mM NaCl, 5 mM
MgCl2, 0.05% IGEPAL, 5% glycerol, 2 mM DTT, 2.5 mM CaCl2,
0.5 mM EGTA in the presence of 250 M ATP and 5 Ci of
[-32P]ATP. For RSK1 HM phosphorylation experiments, first
100 nM activatedMAPKwas incubatedwith 0.5MGST-eluted
MAPKAPK substrates at room temperature for 30 min with
250 M ATP to fully pre-activate MAPKAPK. Then this in situ
phosphorylated RSK1 was added to a mixture of 20 M
GST-HM and5 Ci of [-32P]ATP with increasing amounts
of S100B. Reactions were stopped with protein loading sample
buffer complemented with 20mM EDTA, boiled, and then sub-
jected to SDS-PAGE. The gel was dried before analysis by phos-
phorimaging on a Typhoon Trio scanner (GE Healthcare).
Rates of 32P incorporation into MAPKAPK substrate bands
were obtained by the least squares method using three to five
data points from the linear range of kinetic phosphorylation
curves. Inhibitory constants were determined by fitting a quad-
ratic equation to the measured initial reaction rates. Note that
the presented constants are calculated for a symmetrical bind-
ing mode, and therefore they have to be divided by a factor of 2
to get the asymmetrical binding constant.
Binding Assays and Kinetic Measurements—Steady-state
tryptophan fluorescence was measured with a Synergy H4
TABLE 1
Data collection and refinement statistics










Wavelength (Å) 1.0000 0.9730 0.9677 0.9677
Space group P212121 P212121 P212121 P212121
Cell dimensions
a, b, c (Å) 38.30, 39.24, 172.82 38.31, 38.57, 173.41 37.96, 68.93, 91.49 36.79, 39.93, 178.34
, ,  (°) 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0
Resolution (Å)a 43.20–2.40 (2.46–2.40) 37.65–2.13 (2.19–2.13) 38.12–2.70 (2.77–2.70) 44.59–2.95 (3.03–2.95)
CC1/2a 100.0 (89.4) 100.0 (93.2) 99.5 (71.6) 99.9 (63.8)
Rsyma 3.8 (54.9) 5.5 (82.8) 27.0 (164.6) 15.5 (212.6)
Mean I/Ia 18.69 (2.06) 18.77 (2.07) 9.19 (2.19) 15.85 (1.8)
Completeness (%)a 99.1 (99.2) 99.9 (100) 99.9 (100) 99.9 (100)
Redundancya 4.34 (3.30) 6.43 (6.73) 12.30 (13.08) 17.32 (17.81)
No. of reflectionsa 10,773 (774) 15,160 (1064) 7001 (494) 6056 (444)
Refinement
Rwork/ Rfree 0.2432/0.2907 0.2048/0.2500 0.2034/0.2764 0.2514/0.2785
No. of atoms
All 1512 1568 1570 1576
Ion 4 4 5 4
Water 4 40 14
B-factors
All 76.3 68.2 53.7 89.0
Ion 71.9 56.6 45.4 93.8
Water 70.7 53.5 50.0
Root mean square deviations
Bond lengths (Å) 0.009 0.007 0.022 0.011
Bond angles (°) 1.245 0.930 1.376 0.849
PDB codes 5CSF 5CSI 5CSJ 5CSN
a The highest resolution shell is shown in parentheses.
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(BioTek Instruments) plate reader in 384-well plates. The exci-
tation wavelength was 295 nm, and the emission was detected
at 330 nm. 1 M GST-RSK1CTKD was mixed with increasing
amounts of S100B orCaM.As a negative control, 1MGSTwas
alsomixedwith increasing amounts of S100B (data not shown).
Fluorescence intensity change was only observable in the case
of RSK1-S100B. The experiment was carried out in triplicate.
Themeasured data were fitted by a quadratic binding equation.
Fast kinetic measurements were performed with the
stopped-flow instrument SFM-300 (Bio-Logic) with excitation
at 297 nm. Fluorescence emission from Trp residues was
observed through a 340-nmbandpass filter (ComarOptics). All
reactions were performed at 25 °C in 20 mM Tris, pH 7.5, 100
mM NaCl, 0.5 mM TCEP, 2 mM CaCl2, and 1 mM Ca-EDTA.
Post-mixing GST-RSK1CTKD concentration was fixed to 1 M.
Amplitudes and the observed rate constants of double expo-
nential fits were determined using Origin 7 (OriginLab Corp.).
To determine the off-rate constants, complex samples were
mixed with the RSK1(683–735) peptide.
In direct FP measurements, 50 nM fluorescein-conjugated
reporter peptide was mixed with increasing amounts of S100,
and the FP signal was measured with a Synergy H4 (BioTek
Instruments) plate reader in 384-well plates. In competitive FP
measurements 50 nM labeled reporter peptide was mixed with
S100 in a concentration to achieve60–80% complex forma-
tion. Subsequently, increasing amounts of unlabeled peptide or
GST-RSK1 constructs were added. In all simple competitive
measurements, 20 M S100B was mixed with labeled peptide.
TheKd value for each experiment was determined by fitting the
data to a quadratic or a competition binding equation. Titration
experiments were carried out in triplicate, and the average FP
signal was used for fitting the data with Origin 7.
Gel filtration experimentswere carried out using an in-house
packed 10/300 Superdex 75 column and GF buffer containing
20 mM Tris, pH 7.5, 150 mM NaCl, 1 mM CaCl2, and 25 M
TCEP. Each sample was injected at least two times into the
column. S100B concentration was 1 mM in all cases, which is
much higher than the observed dissociation constant.
Secondary and Solution Structure Determination—CD spec-
troscopymeasurements were carried out on a Jasco J-810 spec-
tropolarimeter using a 0.1-mmwide cuvette in a buffer contain-
ing 20 mM Tris, pH 7.5, 150 mM NaCl, 2 mM CaCl2, 2 mM
Ca-EDTA, and 1 mM TCEP. The free RSK1(683–735) peptide
concentration was 50 M. To obtain the CD spectrum of the
S100B-bound peptide, the spectrum of free S100B (120 M
S100Bmonomer) was subtracted from the spectrumof the pro-
tein complex (50 M peptide and 120 M S100B monomer)
assuming that the secondary structure of S100B does not
change uponRSK1(683–735) binding. Each spectrumwasmea-
sured in triplicate, and the averaged spectra were used for anal-
ysis. The subtracted spectra of the free and the bound peptide
was fitted with BeStSel (26).
All SAXSmeasurements were performed at the BM29 beam-
line at ESRF. Data were analyzed using the ATSAS program
package (27). A dilution series of a concentrated sample of the
gel filtrated RSK1(683–735)-S100B complex was measured
from 8 to 0.4 mg/ml. No concentration effect was observed
during the measurement. The primary data analysis was per-
formed in PRIMUS (Fig. 7). The scattering curve was inter-
preted with CORAL (27). In the CORALmodeling of structure
A, 16-residue long N-terminal, 25-residue long linker, and
4-residue long C-terminal regions weremodeled to the peptide
fragments obtained in the crystal structure (Figs. 6 and 7). Frag-
ments from the crystal structure were treated as rigid bodies,
and only the “invisible” flexible elements were modeled. Solu-
tion scattering from theRSK1CTKDconstructwas determined
with on-line size-exclusion chromatography-SAXS using a
Superdex 75 column. Fit of the crystal structure was deter-
mined by CRYSOL, and an ab initiomodel was generated by 15
independent runofDAMMIN (27). The best fit was achieved by
ensemblemodelingwith EOM, including both ordered and dis-
orderedC-terminal tails (Fig. 10) (28). Ensemblemodelingwith
solely ordered or disordered C terminus resulted in worse fit
and not reliable models (data not shown).
NMRspectrawere recorded on aBrukerAvance III 700 spec-
trometer operating at 700.17MHz for 1H, equippedwith 5-mm
triple-resonance probe head with a z axis gradient. The optimal
spectral dispersion was achieved at 303 K, and this temperature
was selected from a series of HSQC spectra recorded in the
277–320 K range (for both the free and complexed peptide). 1H
chemical shifts were referenced to the internal 4,4-dimethyl-4-
silapentane-1-sulfonic acid standard, whereas 15N chemical
shifts were referenced indirectly via the gyromagnetic ratios.
Both samples had the following compositions: 0.9 mM 15N-
labeled peptide, 20mMMES buffer, pH 6.00, 20mMNaCl, 3mM
NaN3, 2 mM TCEP, 5 mM CaCl2 and 10% D2O. S100B concen-
tration was 2 mM in the complex. Peak assignment and
sequential connectivities were determined from the analysis of
standard three-dimensional HSQC-TOCSY and three-dimen-
sional HSQC-NOESY measurements. Spectra were processed
with TOPSPIN and analyzed using the CARA (29) software
program. Chemical shifts were deposited to the BMRB data-
base under accession number 25873.
Results
S100B Exerts Dual-level Inhibition on ERK2 3 RSK1
Activation—To quantitatively characterize the binding of
S100B to RSK1CTKD, we measured the intrinsic tryptophan
fluorescence change of RSK1 upon S100B binding. Because
none of the MAPKAPKs can bind to CaM, we used it as a
negative control in the experiment. Because neither CaM
nor S100B contains a tryptophan residue, the fluorescent
signal originates from RSK1. A relatively large intensity
decrease (25%) was found in the presence of large excess of
S100B but not in the case of CaM. Themeasured dissociation
constant of the S100B-RSK1CTKD complex was found to be
about 5 M (Fig. 2A).
Activated ERK2 can phosphorylate the CTKD of RSK1 on
Thr-573 in in vitro kinase assays. In turn, activated CTKD can
efficiently phosphorylate an HM containing GST fusion pro-
tein in trans (18). An inhibiting role of S100B on RSK1CTKD
phosphorylation has been recently reported (7). We also find
that S100B clearly impedes RSK1CTKD phosphorylation by
ERK2 in an in vitro kinase assay using recombinantly expressed
and purified components (Fig. 2B). In addition, S100B also
blocks the activity of activated RSK1CTKD on an HM-contain-
Structural Basis of RSK1 Inhibition by S100B





















ing NTKD substrate fragment in trans (Fig. 2C). The calculated
inhibitory constants were found to be around 6M for ERK23
CTKD signaling, which showed a good agreement with the
binding affinity of the S100B-CTKD complex (see above). It is
noteworthy that S100B binding did not completely abolish
CTKD kinase activity on the NTKD HM fragment but only
lowered the reaction rate to40% of the original activity under
saturating conditions. From these observations, we could rule
out that S100B has a CaM-like effect, which is known to exert
activation on CaMKII (30). In conclusion, S100B was shown
here to be a dual-level specific inhibitor of RSK1 activation,
acting both on the ERK23 CTKD and also on the CTKD3
NTKD level.
C-terminal Region of CTKD Mediates High Affinity Binding
to S100B—It was proposed that the S100B-RSK1 interaction
requires the flexible C terminus of RSK1 (7). Interestingly,
ERK2-RSK1 binding also depends on this C-terminal tail (31).
These findings suggest that S100B and ERK2 binding to RSK1 is
mutually exclusive. To show that the two RSK1-binding part-
ners indeed compete for the same RSK1 region, we used FP-
based binding assays with a fluorescently labeled C-terminal
fragment of RSK1. Titrating this labeled reporter peptide
RSK1(712–735) with S100B in the presence of calcium ions
indeed increased its fluorescence anisotropy, indicating direct
interaction (Fig. 3A). In contrast, in the presence of EDTA (or in
the absence of Ca2) no changes in FP were observed (Fig. 3B).
Thus, the interaction seemed to be specific; however, the bind-
ing affinity was found to be low (Kd  30 M). We next
extended the length of the reporter peptide toward the N ter-
minus (residues 689–735). The binding affinity of this
extended peptide, including the inhibitory helix region (L) as
well, was found to be about 6-fold higher compared with the
shorter RSK1 peptide (Fig. 3C).
FP-based binding measurements can also be used to deter-
mine the binding affinities of unlabeled constructs. The disso-
ciation constant of the RSK1CTKD protein as well as different
RSK1 C-terminal fragments were measured in competition
assays. The binding affinity of RSK1CTKD determined in this
assay (4 M) was similarly in the low micromolar range as the
affinity measured by the assay based on monitoring the trypto-
phan fluorescence change upon S100B binding (Fig. 3D).
Extending the peptide length to the end of the core kinase
domain of CTKD(683–735) greatly increased the strength of
complex formation (Kd 40 nM) (Fig. 3, E and F). For this high
affinity complex, the binding stoichiometry can be determined
from the competition curve. In the presence of 20 M S100B,
maximal signal decrease was observed around 10M unlabeled
RSK1(683–735) peptide, indicating an asymmetrical binding
mode. This asymmetry means that a single RSK1(683–735)
peptide binds to one S100B dimer. A similar 1:2 binding stoi-
chiometry was observed in the complex of non-muscle myosin
IIA and S100A4, but it has not been previously observed in any
S100B complex (3). To further confirm the 1:2 binding ratio, we
examined the complex formation in gel-filtration experiments.
Free S100B dimer and free RSK1(683–735) peptides have dif-
ferent elution volumes, and a slight upward shift in the elution
volume is apparent when both components are added, which is
suggestive for complex formation. Mixing the partners in a 1:2
molar ratio gives a homogeneous fast eluting peak, whereas
adding equimolar RSK1(683–735) peptide to S100B chains (2:2
ratio) results in a mixture of the previously identified complex
and free RSK1 peptide (Fig. 3G).
S100 proteins are structurally highly homologous, and there-
fore it is important to determine whether the S100B-RSK1
interaction is specific within the S100 family. Direct binding
between the RSK1(683–735) peptide and S100B, S100A4,
S100A2, and S100P was observed by FP-based binding experi-
ments. Nevertheless, it was found that only S100B was able to
mediate high affinity binding with the RSK1CTKD (Figs. 3H and
4). This result suggests that after anchoring itself to the C-ter-
minal region of RSK1, S100B may form additional specific
interactions with the kinase domain itself. In summary, the
RSK1-S100B interaction seems to be specific among S100 pro-
tein family members.
FIGURE 2. S100B binding inhibits RSK1 activation. A, S100B binding induces a conformational change in GST-RSK1CTKD, which can be monitored by the
change of intrinsic tryptophan fluorescence. The dissociation constant calculated based on this change is 4.8 M. CaM is unable to induce a similar effect on
RSK1 (empty circles). The measurement is representative of at least three sets of independent experiments, and Kd values were calculated from triplicate data
points. Triplicates were independently prepared samples that were assayed at the same time. Error bars show standard deviation from themean. AU, arbitrary
unit. B, presence of S100B inhibits CTKD phosphorylation by ERK2 with a Ki 6.3 M in an in vitro kinase assay. S100B fully inhibits the phosphorylation step
between active ERK2 and the CTKD phosphorylation. C, presence of S100B also acts as an inhibitor also when an NTKD-HM containing construct is phosphor-
ylated in trans,with a Ki 6.1M. Notice that this inhibition is only partial, indicative of a complex inhibitory mechanism on CTKD-mediated phosphorylation
on NTKD. B and C show the mean of three independent reactions, and error bars are standard deviation from the mean. Initial rates of 32P incorporation were
normalized to reactions where S100B was absent.
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The short labeled RSK1(712–735) peptide has a marginal
affinity (30 M) toward S100B; however, it can form a high
affinity complex with ERK2 (0.5–1 M). This phenomenon can
be exploited to investigate co-binding of ERK2 and S100B to
RSK1. At high S100B concentration, ERK2-RSK1(712–735)
complex formation could still be measured both in the pres-
ence or the absence of calcium ions in direct FP measure-
ments (Fig. 3I). In competitive titration experiments using
the RSK1(689–735) peptide fragment, which is a much bet-
ter S100B binder, we could measure the effect of active/in-
active S100B on ERK2-RSK1(689–735) complex formation.
If co-binding can occur then almost identical competitive
titration curves are expected. However, if there is a compe-
tition between ERK2 and S100B then one can measure an
increase in the observed dissociation constant for the ERK2-
RSK1 binding event. Themeasured affinity indeed decreased
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by about 1 order of magnitude (Fig. 3I). This result indicates
that there is a direct competition for the RSK1 tailpiece
between the two binding partners.
Crystal and Solution Structure of the Minimal RSK1-S100B
Complex—For structural studies, a set of RSK1 peptides with
various deletions both from the C- and N-terminal ends of
RSK1(683–735) were made (Figs. 4 and 5A). We found that if
either the C- or the N-terminal part was truncated, the binding
affinity decreased. To visualize the atomic details of the mini-
mized RSK1-S100B interaction, we determined the crystal
structure of the high affinity RSK1(683–735)-S100B complex
(crystal structure A). Unfortunately, only a small N- and C-ter-
minal portion of RSK1 could be built in the crystallographic
model; nonetheless, the structure verified the asymmetric
nature of the complex (Fig. 5, B and C). To improve the quality
of the crystal structure, we attempted protein crystallization
with truncated peptide constructs to decrease the confor-
mational flexibility. An N-terminally truncated peptide
(RSK1(689–735)) gave a very similar crystal structure but with
better resolution and amore interpretable electron densitymap
(crystal structure A) (Fig. 5D). A non-isomorphous crystal
formed with a yet shorter peptide (696–735; crystal structure
B), whereas a nearly isomorphous crystal was obtained with the
peptide 683–720 (crystal structure C) (Fig. 5C). Comparison of
these four structures suggests that the crystallographic models
likely captured different conformations of the interaction (Fig.
5D). In crystal structure B, the middle part of the RSK1 peptide
was also missing, but the C-terminal part showed helical struc-
ture. Similarly to structure A, only the two classical S100 bind-
ing pockets were occupied by the terminal regions of the RSK1
peptide. Structure C displayed a very different structure for the
bound RSK1 peptide. For this peptide (683–720), in agreement
with its lower affinity compared with the full-length peptide
(residues 683–735) or the N-terminally truncated peptide (res-
idues 696–735), one of the two canonical pockets was unoccu-
pied. However, a helical segment from the peptide was found in
the non-conventional binding site of S100B, which is a shallow
groove connecting the two canonical sites as described in Ref. 3.
In structure B, the second canonical S100 binding interface
interacts with a C-terminal helical element of RSK1. This
region of RSK1 has helical propensity in solution and also it
forms a helix when it is bound in the ERK2 docking groove (13).
Moreover, the helical element from structure Cwas found to be
analogous to the surface-oriented side of the bound inhibitory
helix of the previously solved RSK1 structures (Fig. 5C) (13, 14,
32). We propose that structure C captured the S100B-RSK1
complex in a statewhere the interaction between the S100B and
the RSK1 C-terminal segment may be such as in an S100 inhib-
ited complex with full-length RSK1. Superimposing the S100B
complex with an inhibited RSK1 structure via this helical ele-
ment (between residues 700 and 707 with a root mean square
deviation of 1.1 Å for 51 atoms) suggests that the S100B dimer
could help locking the inhibitory helix in its position, and thus
promote its interaction with the core kinase domain while it
simultaneously blocks MAPK binding through the secondary
classical S100-binding interface (Fig. 5E). However, it should be
noted that atomic clashes are apparent between S100B and the
G helix of RSK1 in a model generated by this simple superim-
position. Thus, the G helix must undergo some kind of struc-
tural rearrangement upon S100B binding to be compatible with
the binding mode that was observed in the crystallographic
model C.
All crystal structures included a segment of the L helix
(between residues 697 and 701) on the N-terminal binding side
that is in coil conformation. This apparently key interaction
however does not contain any directed bonds toward S100B. In
structure A, A, and B, the C-terminal binding side is occupied
by the MAPK-binding basic motif with different conforma-
tions. Interestingly, in structure B this segment was helical just
as in the case of the MAPK-bound conformation. This interac-
tion is responsible for the direct competition with ERK2 bind-
ing. In structure C, where this basic motif was truncated, a
helical element appeared next to the N-terminal binding side.
Because different regions showed helical propensity in our
crystal structures, we wanted to investigate the secondary
structure of the bound RSK1(683–735) peptide. We measured
the solution structure using CD spectroscopy (Fig. 6A). The
free peptide is highly flexible and lacks any secondary structural
element, but the bound formcontains a single12-amino acid-
long helical element. For the other characterized asymmetric
S100-binding partner (NMIIA), a much larger helical content
was calculated (60%, 20 residues long) by an identical
method, which was later also confirmed by high resolution
crystal and solution structures (3, 4). This suggests that the
RSK1 binding mode to S100B is different from the NMIIA
binding to S100A4. In addition, these data also suggest that
FIGURE3.CharacterizationofRSK1C-terminal regionas the interactionhot spot forS100Bbinding.A,MAPKbindingC-terminal peptide (RSK1(712–735))
binds weakly to S100B (Kd 30 M). B, in the absence of Ca
2, this interaction is abolished indicating specific binding toward S100B. C, longer C-terminal
fragment, including the inhibitor helix (RSK1(689–735)), bound markedly stronger (Kd  5.2 M). This labeled peptide was used to measure competitive
binding of unlabeled peptides in further experiments. D, GST-RSK1CTKD competed with the labeled long peptide with a Kd of 4.2 M. E, unlabeled RSK1(689–
735) bound somewhat stronger (Kd 1.8M). F, extending this peptide to include the full C-terminal extension of RSK1(683–735), which now also included an
extension before L, increased the binding affinity 2 orders of magnitude (Kd 0.04 M). The shape of the curve indicates asymmetric (2:1) binding because
theS100Bconcentrationwas20M. Eachmeasurement is representativeof at least two sets of independent experimentswhereKdvalueswere calculated from
triplicate data points. Triplicateswere independently prepared samples thatwere assayed at the same time. Error bars showstandarddeviation from themean.
G,gel filtration experiments validated the asymmetric 2:1 stoichiometry in solution. Theupper twopanels showchromatogramsof S100B andpeptide samples.
The lower panels show chromatograms of S100B and RSK1 peptide complexes with a mixed stoichiometry of 2:1 and 2:2. Notice that the peak corresponding
to the free peptide appears only at 2:2 mixing ratio. The panel shows normalized intensity computed according to the maximal absorption at 280 nm
(absorption at 260nm is colored inblack andat 280nm is colored in red).H, summaryof binding affinities betweendifferent S100proteins andRSK1 constructs.
(Asterisks indicate that the fluorescent reporterwas a labeledpeptide fromp53 (p53(17–56)),which is anS100 interactionpartner (41). TheRSK1-based reporter
peptide was used for S100B and S100P measurements.) (See Fig. 4 for details.) I, S100B and ERK2 binding to RSK1 is not independent. Using the fluorescent
reporter RSK1(711–735), it is possible tomeasure only the ERK2-RSK1 binding in the presence of active/inactive S100B. Binding curves in the presence of 2mM
Ca2 (left) and5mMEDTA (middle) showvery similar binding. Competitivebindingexperimentwith a longerpeptide (RSK1(689–735)) showed that thebinding
curves in the presence or absence (black) of Ca2 are clearly different without or in the presence of 10 times molar excess of S100B (right). A clear decrease in
the interaction strength of ERK2-RSK1 binding indicates that ERK2 and S100B binding to RSK1 is mutually exclusive.
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either of the two observed helical element is compatible with
the observed total helical content, but both cannot exist at the
same time.
Based on our multiple crystallographic models, it appears
that the S100B-RSK1 complex can acquiremany possible struc-
tural states. The first model is based on crystal structures A and
A; both canonical binding pockets are filled with the N- and
C-terminal part of the linear motif adopting a coil structure.
The second model is based on crystal structure B; the N-termi-
nal binding region is in coil conformation, but the C-terminal is
helical. The last two possible models are based on structure C.
In these complexes, the N-terminal part is in coil, but it is
extended by a helical intervening part, and theC-terminal bind-
ing region may bind as it is seen in either the A (or A) or the B
crystal structure. Because we wanted to further analyze this
structurally diverse, apparently fuzzy complex, as revealed by
x-ray crystallographic analysis, we used SAXS to obtain at least
low resolution structural information about the shape of the
complex in solution. We were able to measure high quality
SAXS from an isolated complex with the RSK1(683–735) pep-
tide (Fig. 7). In all crystal structures, only small peptide frag-
ments could be located in the electron density. Using SAXS
data, however, we could simulate the whole complex using the
above described four templates (Fig. 6B). In these simulations
the “crystallographically” invisible parts were ab initiomodeled
using a program called CORAL (27). Out of the four structural
models, only the first one (based on structure A and A) fit the
obtained SAXS curve, and therefore this describes the solution
structure of the RSK1-S100B complex the best (Figs. 6 and 7).
The simulated models have high flexibility between the two
anchor positions; therefore, it can be considered as a clamp-
type fuzzy complex (19). From10 independent simulations, two
types of clusters were observed as follows: one with a free and
one with an S100-bound N-terminal part (Fig. 7). This N-ter-
minal flanking segment seems to be responsible for a large
increase in the binding affinity (Figs. 4 and 5A). Unfortunately,
this site on S100B is close to a crystal packing interaction sur-
face; therefore, this additional interaction remains hidden in
our crystal structures. To further characterize this flanking ele-
ment, we performed mutational scanning on the first six resi-
dues (Figs. 4 and 5A). We found that the first two residues do
not directly contribute to the binding, but if either residues
685–686 or 687–688 were mutated to Ala, the binding affinity
decreased with an order of magnitude. We assume that the
hydrophobic Leu-686 and basic His-688 are most likely the key
residues determining the high affinity binding of RSK1(683–
735) to S100B.
As an additional analysis, we measured the changes in the
solution structure of this minimal RSK1 peptide by NMR spec-
troscopy. We characterized the RSK1(683–735) peptide in free
form and performed peak assignment at 303 K from the three-
dimensional TOCSY-HSQC and NOESY-HSQC measure-
ments. Already the narrow signal dispersion of theHSQC spec-
trum informed us about the disordered nature of this free RSK1
tail fragment. Addition of excess S100B under identical condi-
tions resulted in changes in the spectrum (Fig. 7E). The com-
plex had an increased molecular mass and as a consequence a
different tumbling time in solution.As changesweremonitored
from the 15N RSK1 peptide side (S100B protein was unlabeled),
the consequence of complex formation would be observable as
shifted and broadened peaks and also peaks broadened below
the detection limit in the HSQC spectrum.
Unfortunately, we were unable to assign the complex spec-
trum under these experimental conditions. Nevertheless, if we
assume that close peaks in theHSQC spectra correspond to the
same amino acid, we could gain residue level information of the
changes in the chemical environment of the RSK1peptide upon
complex formation. Based on the overlay of the spectra, it
appears that many peaks showed no or little chemical shift
changes. These are the residues that belong to the N-terminal
flanking and the intervening parts (for example Val-694, Gly-
696, Ser-707, and Lys-709 remainedmostly unchanged, see Fig.
5). Although 54 peaks (including minor peaks) were detectable
for the free peptide, only 47 peaks were present in the spectrum
of the complex (Fig. 7E). Disappearing peaks correspond to res-
idues involved in direct binding interaction with intermediate
exchange. However, these resonances can also belong to the
shifted, newly appearing broad peaks. These changes clearly
affect the C-terminal binding side (residues 724–730) and res-
idues from the N-terminal side (like Ala-697 or Ala-704); they
are in full accordance with the crystallographic model ( Fig. 5)
and indicating that these regions could provide the “clamps” of
the fuzzy complex. In addition, the N-terminal flanking part
was also changed upon binding (e.g. Leu-686). The lack of dra-
matic changes in signal dispersion upon complex formation
suggests that there are no new secondary structural elements
forming in the RSK1 peptide. This suggests that the observed
helical content by CD spectroscopy is due to transient helix
formation. Overall, these observations corroborate the exist-
ence of a fuzzy complex and are in agreement with the crystal-
lographic analysis of the RSK1-S100B complex.
Rapid Kinetic Experiments Reveal That S100B Binding to
RSK1 Involves Both Conformational Selection and Induced
Fit—The inherent tryptophan fluorescence change of RSK1
upon S100B binding (Fig. 2A) could be used to decipher the
kinetic mechanism of the interaction. In stopped-flow experi-
ments, we were able to follow RSK1-S100B complex formation
in real time bymixing RSK1with S100B as well as tomonitor its
dissociation by mixing the complex with a “chaser” peptide
from RSK1 (Fig. 8). Both the observed association and dissoci-
ation transients could be fitted by double exponential func-
tions. The observed rate constants of the first and second
FIGURE 4. Fits of the fluorescence polarization binding measurements. A, direct (left) and competitive (middle, right) FP measurements for different S100
proteins. In competitive experiments, unlabeled RSK1(683–735) (middle) or RSK1CTKD (right) was used as a competitor. In experiments with S100A2, S100A4,
and S100A10, a fluorescein-labeled p53 reporter peptide (p53(17–56)) was used as a reporter peptide. B, competitive FP measurements with unlabeled
truncated or mutated RSK1 peptides using the S100B-RSK1 peptide reporter system. Titration experiments without fits to a direct or a competitive binding
equation did not showbinding or complete competitionwith the labeled reporter peptide, whichwas regarded as an indication for nonspecific binding. Each
measurement is representative of at least two sets of independent experiments where Kd values were calculated from triplicate data points. Triplicates were
independently prepared samples that were assayed at the same time. Error bars show standard deviation from the mean.
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phases of the association transients showed a decreasing and an
increasing tendency, respectively, with increasing S100B con-
centration. The rate constants of both phases reached satura-
tion at a relatively low S100B concentration (Fig. 8, C and D).
These profiles are indicative of the presence of both conforma-
tional selection (first phase) and induced fit (second phase) pro-
FIGURE 5. Structural properties of the S100B-RSK1 complex. A, summary of binding affinities between S100B and various truncated RSK1 peptide con-
structs. (See Fig. 3 and 4 for details.) Removal of small regions at both sides greatly influences the binding affinity. The sequence logo was generated by using
vertebrate (n  40, non-redundant) RSK1/2 sequences. Point mutations are highlighted in the sequence. The underlined sequences were modeled into the
corresponding complex crystal structure, although others could not be built in. Dotted lines indicate some register ambiguity in the interpretation of the
corresponding crystallographic model. In the autoinhibited MAPK-bound state residues between 690 and 707 form the L helix, and the C-terminal tail from
712 is involved in MAPK binding (13). B, Matthews probabilities of crystal structure A calculated for apo-S100B and for 2:1 and 2:2 complexes (20). In all
determined structures the2:1 complexwas themostpreferred content.C, FoFc simulatedannealingomitmap (contouredat 2) around theRSK1peptides (red)
for the determined crystal structures A, B, and C. The S100 monomers are shown in gray or light gray schematic representation. Both docking pockets of the
S100B are filled by the N- and C-terminal fragments of the RSK1 peptide in structure A, A, and B; however, only the N-terminal part along with a helical
extension is present in structure C.D, detailed view of the observedN- and C-terminal parts of the presented structural states. The N-terminal bindingmode in
structure A and B is highly similar. Bound calcium ions are shown with black spheres. The binding fragments from structure A is colored in orange. E, crystal
structure C can be superimposed to an inactive RSK1CTKD structure (green) via their common helical region (red). (revD: the docking motif for ERK2). The
inset shows that S100B binds to the solvent-accessible side of the inhibitor helix (L). Black arrow indicates steric clash between the G helix of RSK1 and the
superimposed S100B.
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cesses. As dissociation was dependent on chaser peptide con-
centration, dissociation rate constants were determined by
linear extrapolation to zero chaser concentration (Fig. 8,G and
H). Based on the exponential approximations (Fig. 8), we con-
structed the kinetic model shown in Fig. 9, which we used for
global fitting kinetic analysis (Fig. 10). The results of this anal-
ysis (Fig. 10,A andB) were in good agreementwith those result-
ing from experimental fits (Fig. 9). In the proposedmodel RSK1
displays conformational heterogeneity, termed autoinhibited
and released state, indicating the position of L helix. The
interaction of the released species with S100B is followed by an
isomerization step. Note that S100B binding by the predomi-
nant autoinhibited species is not favorable. S100B binding
therefore can be described as a combination of conformational
selection and induced fitmodel (Fig. 10B). First, S100B can only
bind to the free C-terminal tail. After the formation of the fuzzy
complex, the anchored S100B can mediate further interactions
with the kinase domain. The population of this “S100B-inhib-
ited” state is44%, and it can share structural relationshipwith
our crystal structure C.We speculate that this latter complex is
responsible for the inactivation of the activated CTKD domain
of RSK1.
To validate the apparent conformational heterogeneity of
RSK1, we attempted to analyze the RSK1CTKD construct by
FIGURE6.Solution structureof theS100B-RSK1complex.A,CDspectra of free (red) andRSK1(683–735)-bound (black) S100B is shownon the left side and the
CD spectra of free (red) and S100B-bound (black) RSK1(683–735) peptide is shown on the right side. An increase in the helical content upon complex formation
can be observed without major changes in the S100B structure itself. Deconvolution of the difference spectra by the program BeStSel reveals an13-amino
acid-long single helix in the bound state (the free peptide is completely disordered) (25). B, based on the crystallographic models, using two N- and two
C-terminal RSK1-interacting fragments, four types of S100B-RSK1(683–735) complexes can be constructed. Eachmodel was refined against high quality SAXS
data, but only one of themodels, corresponding to crystal structure A,matched the experimental SAXS curve (Fig. 7). The best fit from 10 independent CORAL
simulations is shownalongwitha superpositionof five randomly chosen simulated structures. For simulations, flexiblepartsweremodeledandare shownhere
with spheres, whereas the rest was treated as rigid.
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SAXS (Fig. 10C). Unfortunately, all attempts to measure scat-
tering of the S100B-RSK1CTKD complex failed, because the
complex dissociated under gel filtration. Moreover, obtaining
good SAXS data on the RSK1CTKD construct alone turned out
to be technically challenging due to the protein’s aggregation
tendency. Fortunately, on-line gel filtration of the S100B-
RSK1CTKD complex without Ca2 finally gave useful scattering
data on the RSK1CTKD construct. The measured pattern
showed an acceptable fit with anRSK1model obtained from the
ERK2-RSK1CTKD heterodimeric crystal structure (  1.00)
(Fig. 10C) (13). In contrast, a more reasonable model ( 0.88)
could be described as an ensemble of both “autoinhibited” and
FIGURE 7. Detailed analysis of the solution structure of the fuzzy S100B-RSK1 complex. A, Guinier fit (red lines) to the obtained scattering curve in the
concentration series. The measured concentrations of the isolated complex were 8.3, 3.8, 2.0, 0.8, and 0.5 mg/ml (from cyan to black). The curves were scaled
and translated for clarity. Eachmeasurementwas averaged from10 independently recorded frames. The scatteringof thebufferwasdeterminedbymeasuring
10 frames before and after the samplemeasurements. Error bars show standard deviation from themean. The calculated Rgwas concentration independently
1.94 nm. B, experimental curve (black line) superimposedwith the reconstructed scattering fromdistance distribution function (red line). Error bars are showed
with gray lines. C, distance distribution function (so-called P(r) function) of the S100B-RSK1(683–735) complex derived from the experimental curve. The
maximal dimensionwasdetermined tobe6.5 nm, and the calculatedRgwas identicalwith theRg from theGuinier fit (1.94 nm).D, twogroups of independently
simulated structures were identified by clustering. Representatives of the clusters are shown. The main differences among the clusters are the N-terminal
conformations, which are either free or S100-bound. Note that this heterogeneous (10–15 residue long) N-terminal region is responsible for a large affinity
increase in peptide truncation experiments. The average diameter of the simulated complexes is around 5 nm. The small tail in the P(r) function up to 6.5 nm
canbe an effect of the fuzziness of the intermediate and flankingpart of the RSK1peptide. E,overlay of theHSQC spectra of the free (red) and S100B complexed
(blue) 15N-labeled RSK1(683–735) peptide. Partial assignment of the free peptide is shown. The cloning “GS” artifacts are highlighted as “Gly” and “Ser.” (Bold
residueswere assignedwith larger confidence and low confidence ismarkedwith italic characters.) Note that a fraction of peaks completely disappearedupon
complex formation (e.g. Arg-726, Val-727, and Arg-728), whereas a fraction of peaks shows significant changes (e.g. Gln-692, Ser-703, or Leu-735). The
remaining peaks do not show large changes upon S100B binding (e.g. Ser-687, Leu-714, or Ser-720).
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“released” states of theCTKD (Fig. 10D). Although thismay not
be regarded as unambiguous validation of all the structural
models proposed, it lends support to some aspects of the com-
plex kinetic model.
Discussion
CaMKdomains share similar architecture and therefore sim-
ilar regulation. Their C-terminal extensions usually have an
inhibitory effect on the kinase domain, and this autoinhibition
needs to be released before the kinase can become enzymati-
cally active. In many cases, this is achieved through CaM bind-
ing. InMAPKAPK-type kinases, the activation loop needs to be
phosphorylated by a MAPK. Then the phosphorylated activa-
tion loop and the autoinhibitory element must go through sub-
stantial remolding at the active site (33). Hartman et al. (7) have
recently reported that S100B can bind to RSK1 and suggested
that this interaction is positioned to the same RSK1 C-terminal
region where ERK2 also binds (12). However, the possibility
that S100B may bind to the autoinhibitory RSK1 C-terminal
region has not been postulated before. Based on our results, we
conclude that CaM and S100B binding is structurally similar.
However, their binding to cognate CaMK domains can have
dramatically different functional readouts. CaM binding pro-
motes CaMKII activity by stabilizing an open and active con-
formation of the kinase (see Fig. 1A), whereas S100B binding
inhibits RSK1 activity, possibly by stabilizing a closed and auto-
inhibited form of RSK1, in addition to also directly blocking
ERK2 recruitment. In the work of Hartman et al. (7), it was
stated that S100B binding had no effect on the phosphorylation
of the RSK hydrophobic motif. In the light of our in vitro kinase
assay data and considering that MAPKAPK HM phosphoryla-
tionmay occur reportedly in trans as well (34), this discrepancy
may be explained by the insensitivity and/or nonspecific nature
of the used antibody in the former report.
X-ray crystallographic, SAXS, and NMR-based structural
analysis indicate that S100B forms a fuzzy complex with the
C-terminal tail of RSK1. Disordered binding regions (IDRs) of
proteins usually show flexibility only in their unbound state, but
FIGURE 8. Tryptophan fluorescence-based kinetic experiments, exponential analysis. A, binding traces of GST-RSK1CTKD and S100B fitted with a double
exponential function. (TheS100B concentrationdecreases from red toblue.) GST-RSK1CTKD Trp fluorescence transientswere recordedupon rapidlymixing1M
RSK1CTKD with increasing concentrations of S100B2 (0.125, 0.25, 0.5, 1, 2, 4, 8, 16, 32, 64, and 128M) in the stopped-flow instrument (post-mix concentrations
are stated). B, amplitudes of the fitted exponentials of S100B-RSK1CTKD binding, expressed relative to the calculated maximal Trp fluorescence change. The
amplitudes for the first exponential are colored in green and for the second exponential in blue. The total amplitudes (in black) were fit to a quadratic equation
(Kd 1.3 M). C, observed rate constants of the first exponential phase. Note the decrease in the pseudo-first order region (20 M S100B). D, observed rate
constants of the second exponential phase. E,dissociation of the S100B-RSK1CTKD complexmonitored in kinetic chasing experiments. Trp fluorescence change
wasmonitored upon rapidlymixing a premixture of GST-RSK1CTKD (1M) and S100B (15M)with increasing amounts of isolated RSK1 peptide (6.25, 9.38, 12.5,
18.75, 25, and 37.5M). (The chaser concentration decreases from red to blue.) Traceswere fittedwith a double exponential function. F, amplitudes of the fitted
exponentials of thedissociation experiments, expressed relative to the calculatedmaximal Trp fluorescence change. Color scheme is identical toB.G,observed
rate constants of the fast step (green squares) dependon the applied chaser peptide concentration. The increasing tendencyof dissociation rate constantswith
chaser peptide concentration is indicative of active destabilization of the S100B-RSK1CTKD complex by the peptide. The actual off-rate constants were deter-
mined using linear extrapolation (y intercept). H, rate constant of the slower step (blue squares) is independent of chaser peptide concentration. See Fig. 9 for
comparison of parameters determined by global fitting (Fig. 10) and exponential analysis (this figure). Themeasurement is representative of at least three sets
of independent experiments, and error bars represent the standard deviations of the fitting.
FIGURE 9. Comparison of the kinetic parameters based on the exponential analysis and the global fit. The proposedmodel consists of two consecutive
steps involving conformational selection or induced fit based steps. Free RSK1 is in a mixture of S100B binding competent and incompetent states (1st step).
After complex formation (2nd step), the primary RSK1-S100B complex undergoes an additional isomerization step (3rd step; see also model in Fig. 10B). The
kinetic constants were named based on the upper equation for the global fitting and according to Fig. 8 for the exponential analysis. Accurate assignation of
ki and kon was not possible with our experimental setup. The listed parameters are the calculated lower limits for these parameters. However, these two
variables show definite covariance, and simultaneous changes in their values do not influences the global, observed Kd, eq. Increasing the speed of these
parameters results in a lowered fraction of the released state and therefore results in a more dominant conformational selection model.
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upon partner binding they fold (35). In contrast, fuzzy com-
plexes retain a degree of flexibility even in their bound form
(19). They could be prevalent in interactomes, but they cur-
rently stay mostly uncharacterized due to limitations of our
experimental approaches. Capturing static interactions from a
fuzzy complex is challenging, and determining the in-solution
structural ensemble is almost impossible.Wemanaged to crys-
tallize the minimal S100B-RSK1 complex in three different
binding modes regarding the structure of the RSK1 C-terminal
region. This was necessary to obtain a reliable structural
ensemble by SAXS as experimentally determined crystallo-
graphic structural states could be used to model in-solution
scattering. Interestingly, it was the fuzziest crystallographic
model with only two small anchoring contacts between the
flexible RSK1 C-terminal region and the dimeric S100B protein
that matched the determined in-solution molecular ensemble
the best. In this complex, a large part of the bound peptide is not
involved in making contacts and is highly unstructured, which
we also proved by solution NMRmeasurements. The fuzziness
of the complex and the observed increase in helical content
upon binding raise the question as to where and how a helix
may form, albeit likely only transiently. Our diverse crystallo-
graphic models suggest that the shallow binding interface of
S100B is able to interactwith helical partners. Also, the distance
between the two observed anchored regions is26 Å, which is
connected by a 25-residue-long flexible linker. It is possible that
the propensity for helix formation within this intervening
region is highly increased because the motion of this relatively
large linker is sterically limited by a clamping mechanism. It is
noteworthy that a similar shallow groove of S100A4 mediates
interaction with a helical peptide segment of NMIIA (3, 4).
The described mode of S100B binding directly to RSK1 is
possible only if the inhibitory L helix is released from the core
kinase domain. If this is not the case, then S100B needs to pull
out the helix from the active site. The first case would be a
classical conformational selection mechanism, and the second
one is an induced fit scenario. In theory, they can both be pres-
ent, but our measured kinetic data suggest that the primary
binding of S100B to RSK1CTKD can only be described with the
conformational selectionmodel. However, we also observed an
induced fit step where the bound S100B further interacts with
the kinase domain. This latter interaction could explain that
S100B allosterically inhibits the activity of phosphorylated
RSK1. Based on one of the crystallographic models (crystal
structure C), it is likely that S100B can interact with the inhib-
itory L helix in situ, and thus it may increase its stability in the
autoinhibited versus the released state of RSK1 CTKD. Never-
theless, this complex is rather unlikely to form because the G
FIGURE10.Assemblyof theS100B-RSK1complex.A, stopped-flowbasedkineticanalysis (presented inFig.8)byglobal fittingbasedonthemodel shown inB (black
lines) (seealsoFig.9). (TheS100Bconcentrationdecreases from red togreen.)B,proposedkineticmodel forRSK1-S100Binteractionwiththedeterminedrateconstants.
In the unbound state, the kinase populates two forms: autoinhibited (99%) and released (1%). Regarding S100B binding, it is the released form that is capable of
binding to S100B; therefore, this is an example for conformational selection. We hypothesized that the flexible C-terminal tail is the major source of the apparent
conformational heterogeneityofRSK1,because thisbinding stephasaKd10nM (6.97 s
	1/676M	1 s	1). This value roughly corresponds to the strongsteady-state
binding affinity of an isolated peptide comprising this flexible C-terminal RSK1 tail (as the Kd of the S100B-RSK1(683–735) complexwas determined to be 40 nM). The
S100B-bound complex shows an additional isomerization step, as an example of induced fit, from the “fuzzy” complex into an “S100B-inhibited” state. An additional
but kinetically blocked route is shown in gray. The theoretical Kd for this reaction is 2.85 M. C, small angle x-ray scattering of RSK1CTKD. The fit of the computed
scattering curve based on the autoinhibitory state obtained from the ERK2-RSK1 crystal structure (13) is highlighted in red ( 1.00). In the inset the crystal structure
is displayedas superimposed to the averagedab initiomolecular envelope calculatedbyDAMMIN (27).D,most reasonable fit fromEOMrefinement (28) consistedof
an ensemble of structureswithmixed autoinhibitory and released states ( 0.88).
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helix is in steric clash in the superimposed models. Releasing
the L inhibitory helix can cause a high degree of structural
rearrangement, which can be ideal for the S100B bound inhib-
itory complex. From a kinetic perspective, the proposed mech-
anistic model can also be considered as a thermodynamic box
(Fig. 10B). S100B binding to the autoinhibited state of the
kinase can then directly result in the S100B inhibited complex,
with a theoretically calculated Kd of 3 M, which cannot be
neglected compared with the observed binding constants.
However, it is clear that that this path is kinetically blocked.
Could the rearrangement of the G helix be the reason for this
kinetic block? Tentatively, the answer is yes; however, to
describe this presumed S100B-RSK1 inhibitory complex in
more detail, an atomic resolution structure of S100B in com-
plex with the RSK1 CTKD is needed.
In malignant melanoma, the MAPK/ERK pathway is usually
up-regulated by activatingmutations of upstream kinases. This
could result in hyperphosphorylation and hyperactivation of
RSK1. However, overexpression of S100B in melanoma pro-
tects RSK1 against active ERK2 and in turn fromautophosphor-
ylation. The mechanistic explanation why S100B inhibition of
RSK1 activation is a hallmark feature in melanoma is not
understood. Hartman et al. (7) also showed that the subcel-
lular localization of RSK1 is altered by S100B, which could
shift remaining RSK1 activity into the cytoplasm. These
effects may be beneficial to melanoma cells by negatively
affecting important tumor suppressor proteins such as
DAPK1, LKB1, or TSC2 (10, 36, 37). Although little is known
about the precise mechanism behind RSK1 localization, cel-
lular studies showed that activation of the NTKD involving
both AL and HM phosphorylation is essential to nuclear
accumulation (38). CTKD inhibition by S100B can directly
affectHMphosphorylationandtherefore theNTKDALphos-
phorylation, too.
Before this study, three binding pockets were identified on
S100B (Fig. 11A) (39). Selective targeting of these sites is already
a promising opportunity for the treatment of malignant mela-
noma (9). Here, we showed that the fuzzy complex uses site 1
and site 2 simultaneously, whereas the inhibitory complex
involves an asymmetric fourth binding site, which is placed
between the classical symmetric binding pockets (Fig. 11). Tar-
geting the classical binding sites can inhibit interactions of
S100B indiscriminately, but targeting of this middle binding
pocket may be a highly selective inhibitor for the assembly of
the S100B-RSK1 inhibitory complex. Based on the observation
that primary complex formation only yields the fuzzy complex
where this fourth binding site remains free, this novel site may
be a potent switch that can freeze the S100B-RSK1CTKD com-
plex into aCaMK-CaMtype complex. Stabilization of this latter
conformation would presumably promote activation of the
kinase, thus turning S100B into an activator of the ERKpathway
rather than an inhibitor. Overall, our data and structural mod-
els potentially may open up avenues for selective modulation,
inhibition and activation alike, of RSK1 activity. In turn, this
could enable mapping out the physiological consequences of
the apparent signaling cross-talk between a Ca2-dependent
protein and an important kinase regulator of cell growth.
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